Relief of hot flashes with escitalopram in non-depressed menopausal women in Japan: Results of a retrospective analysis


Purpose: Hormone therapy (estrogen with or without progestin) remains the gold standard treatment for hot flashes in menopausal women, but concerns for the risk of hormone therapy have resulted in its decline and a demand for nonhormonal treatments with demonstrated efficacy for hot flashes. Aim of this study was to examine the efficacy of selective serotonin reuptake inhibitor escitalopram on hot flashes in a healthy sample of non-depressant menopausal women in Japan. Methods: We retrospectively analyzed the medical records of 11 menopausal patients with hot flashes, who received escitalopram (10 mg daily) for 2 weeks between March and August 2012. Hot flashes severities and scores were recorded on a scale of 0 to 10 points, at beginning and end of 2 weeks treatment. Results: At 2 weeks of therapy, 9 of 11 patients reported significant decreases in hot flash frequency and severity, but the remission of the symptom was not observed in 2 patients. Speed of relief from hot flashes was rapid (within one week). Conclusions: Escitalopram 10 mg/day may be a prompt and effective option for treating hot flashes in menopausal women who do not want to use hormone replacement therapy.

Share and Cite:

Mori, C. and Imai, A. (2012) Relief of hot flashes with escitalopram in non-depressed menopausal women in Japan: Results of a retrospective analysis. Health, 4, 893-896. doi: 10.4236/health.2012.410136.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Pearce, J., Hawton, K. and Blake, F. (1995) Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. British Journal of Psychiatry, 167, 163-173. doi:10.1192/bjp.167.2.163
[2] Dennerstein, L. (1996) Well-being, symptoms and the menopausal transition. Maturitas, 23, 147-157. doi:10.1016/0378-5122(95)00970-1
[3] Rossouw, J., Anderson, G., Prentice, R., LaCroix, A., Kooperberg, C., Stefanick, M., Jackson, R., Beresford, S., Howard, B., Johnson, K., Kotchen, J. and Ockene, J. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. Journal American Medical Association, 288, 321-333. doi:10.1001/jama.288.3.321
[4] Dobkin, D., Menza, M., Allen, L., Marin, H., Bienfait, K., Tiu, J. and Howarth, J. (2009) Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study. Annals of Clinical Psychiatry, 21, 70-76.
[5] Vickers, M., MacLennan, A., Lawton, B., Ford, D., Martin, J., Meredith, S., DeStavola, B., Rose, S., Dowell, A., Wilkes, H., Darbyshire, J. and Meade, T. (2007) Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): A randomised controlled trial of hormone replacement therapy in postmenopausal women. British Medical Journal, 335, 239-244. doi:10.1136/bmj.39266.425069.AD
[6] Rodriguez, C., Patel, A., Calle, E., Jacob, E. and Thun, M. (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal American Medical Association, 285, 1460-1465. doi:10.1001/jama.285.11.1460
[7] Shumaker, S., Legault, C., Rapp, S., Thal, L., Wallace, R., Ockene, J., Hendrix, S., Jones, B.r., Assaf, A., Jackson, R., Kotchen, J., Wassertheil-Smoller, S. and Wactawski-Wende, J. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The women’s health initiative memory study: A randomized controlled trial. The Journal of American Medical Association, 289, 2651-2662. doi:10.1001/jama.289.20.2651
[8] Fletcher, S. and Colditz, G. (2002) Failure of estrogen plus progestin therapy for prevention. The Journal of American Medical Association, 288, 366-368. doi:10.1001/jama.288.3.366
[9] Nelson, H., Humphrey, L., Nygren, P., Teutsch, S. and Allan, J. (2002) Postmenopausal hormone replacement therapy: Scientific review. The Journal of American Medical Association, 288, 872-881. doi:10.1001/jama.288.7.872
[10] Boraz, M.A., Simkin-Silverman, L.R., Wing, R.R., Meilahn, E.N. and Kuller, L.H. (2001) Hormone replacement therapy use and menopausal symptoms among women participating in a behavioral lifestyle intervention. Preventive Medicine, 33, 108-114. doi:10.1016/S0091-7435(01)80006-2
[11] Imai, A., Matsunami, K. and Takagi, H., Ichigo, S. (2012) New generation nonhormonal management for hot flashes. Gynecologic Endocrinology, in press. doi:10.3109/09513590.2012.705380
[12] Loprinzi, C., Sloan, J., Stearns, V., Slack, R., Iyengar, M., Diekmann, B., Kimmick, G., Lovato, J., Gordon, P., Pandya, K., Guttuso, T.J., Barton, D. and Novotny, P. (2009) Newer antidepressants and gabapentin for hot flashes: An individual patient pooled analysis. Journal of Clinical Oncology, 27, 2831-2837. doi:10.1200/JCO.2008.19.6253
[13] Pinkerton, J., Stovall, D. and Kightlinger, R. (2009) Advances in the treatment of menopausal symptoms. Women’s Health, 5, 361-384. doi:10.2217/whe.09.31
[14] Sideras, K. and Loprinzi, C. (2010) Nonhormonal management of hot flashes for women on risk reduction therapy. Journal of National Comprehensive Cancer Network, 8, 1171-1179.
[15] Loprinzi, C., Qin, R., Balcueva, E., Flynn, K., Rowland, K.J., Graham, D., Erwin, N., Dakhil, S., Jurgens, D. and Burger, K. (2010) Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. Journal of Clinical Oncology, 28, 641-647. doi:10.1200/JCO.2009.24.5647
[16] Freeman, E., Guthrie, K., Caan, B., Sternfeld, B., Cohen, L., Joffe, H., Carpenter, J., Anderson, G., Larson, J., Ensrud, K., Reed, S., Newton, K., Sherman, S., Sammel, M. and LaCroix, A. (2011) Efficacy of escitalopram for hot flashes in healthy menopausal women: A randomized controlled trial. The Journal of American Medical Association, 305, 267-274. doi:10.1001/jama.2010.2016
[17] Soares, C., Arsenio, H., Joffe, H., Bankier, B., Cassano, P., Petrillo, L. and Cohen, L. (2006) Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: Impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause, 13, 780-786. doi:10.1097/01.gme.0000240633.46300.fa
[18] Soares, C., Thase, M., Clayton, A., Guico-Pabia, C., Focht, K., Jiang, Q., Kornstein, S., Ninan, P., Kane, C. and Cohen, L. (2010) Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause, 17, 700-711.
[19] Sloan, J., Loprinzi, C., Novotny, P., Barton, D., Lavasseur, B. and Windschitl, H. (2001) Methodologic lessons learned from hot flash studies. Journal of Clinical Oncology, 19, 4280-4290.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.